Respondents’ profile
| Respondents | Total (n=235) | Primary care (n=132) | Secondary care (n=103) |
| Number of respondents | 235 | 132 | 103 |
| Austria | 24 | 12 | 12 |
| Switzerland | 50 | 35 | 15 |
| Sweden | 61 | 31 | 30 |
| UK | 100 | 54 | 46 |
| Percentage of physicians responding that they treat | |||
| Less than 50 patients with T2D/month | 24 | 27 | 20 |
| 50–99 patients with T2D/month | 46 | 55 | 33 |
| 100–149 patients with T2D/month | 19 | 13 | 26 |
| 150–199 patients with T2D/month | 6 | 2 | 10 |
| More than 200 patients with T2D/month | 6 | 3 | 11 |
| Percentage of physicians responding that they treat | |||
| 2–5 patients with IDegLira/month | 47 | 59 | 31 |
| 6–10 patients with IDegLira/month | 27 | 27 | 28 |
| 11–15 patients with IDegLira/month | 9 | 6 | 14 |
| More than 15 patients with IDegLira/month | 17 | 8 | 27 |
Across all countries, a total of 4261 physicians and 195 nurses were invited to complete the survey, and a total of 235 physicians and 0 nurse completed the survey.
NB: The percentage of respondents is reported to the nearest whole number so the sum may not total to 100% exactly.
IDegLira, insulin degludec/liraglutide; T2D, type 2 diabetes.